Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains
Hannah Reimann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Michael Aigner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Anita N. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Julia Zeun(Friedrich-Alexander-Universität Erlangen-Nürnberg), Johan Verhagen, Simon Völkl(Universitätsklinikum Erlangen), Andréas Mackensen(University Medical Center Freiburg), Kilian Schober(Friedrich-Alexander-Universität Erlangen-Nürnberg), Vanessa Lang(Friedrich-Alexander-Universität Erlangen-Nürnberg), Carolin Moosmann(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 3
Related Papers
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
|Science Immunology|2022|280
Absence of T-regulatory cell expression and function in atopic dermatitis skin
|Journal of Allergy and Clinical Immunology|2005|272
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells
|Cancer Immunology Immunotherapy|2000|240